Neuroendocrine-Immune Mediator Coordination and Disarray in Critical Illness

Pediatric Critical Care

Volumn , Issue , 2006, Pages 1462-1473

  Felmet, Kathryn ^a   Carcillo, Joseph ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 44149109074     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-032301808-1.50098-5     Document Type: Chapter

References (76)

1. Zaloga GP, Marik P Hypothalamic-pituitary-adrenal insufficiency. Crit Care Clin 2001, 17:25-41.
2. Chikanza IC, Grossman AS Hypothalamic-pituitary mediated immunomodulation: arginine vasopressin is a neuroendocrine immune mediator. J Rheumatol 1998, 37:131-136.
3. Basic and clinical endocrinology 1997, Appleton and Lange, Stamford, CT. ed 2. F.S. Greenspan, G.J. Strewler (Eds.).
4. Chicanza IC Prolactin and immunomodulation: in vitro and in vivo observations. Ann N Y Acad Sci 1999, 876:119-130.
5. Guyton AC, Hall JH Textbook of medical physiology 1996, WB Saunders, Philadelphia.
6. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405:458-462.
7. Crofford LJ, Sano H, Karalis K, et al. Corticotropin releasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. J Immunol 1993, 151:1587-1596.
8. Karalis K, Sano H, Redwine J, et al. Autocrine or paracrine inflammatory actions of corticotropin releasing hormone in vivo. Science 1991, 25:421-423.
9. Amoo-Lamptey A, Dickman P, Carcillo JA Comparative pathology of children with sepsis and MOF, pneumonia without MOF, and MOF without infection. Pediatr Res 2001, (abstract).
10. Vermes I, Beishuizen A The hypothalamic-pituitary-adrenal response to critical illness. Best Pract Res Clin Endocrinol Metab 2001, 15:494-507.
11. Vermes I, Beishuizen A, Hampsink RM, et al. Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: possible role of endothelin and atrial natriuretic hormone. J Clin Endocrinol Metab 1995, 80:1238-1242.
12. Ehrhart-Bornstein M, Hinson JP, Bornstein SR, et al. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev 1998, 19:101-143.
13. Marx C, Ehrhart-Bornstein M, Scherbaum WA, et al. Regulation of adrenocortical function by cytokines relevance for immune-endocrine interactions. Horm Metab Res 1998, 30:416-420.
14. Toth IE, Hinson JP Neuropeptides in the adrenal gland: distribution, localization of receptors, and effects of steroid hormone synthesis. Endocr Res 1995, 21:39-51.
15. Beishuizen A, Thijs LG Relative adrenal failure in intensive care: an identifiable problem requiring treatment?. Best Pract Res Clinical Endocrinol Metab 2001, 15:513-531.
16. Beishuizen A, Bonte HA, Vermes I Patterns of corticosteroid binding globulin and free cortisol index during severe sepsis and multi trauma. Intensive Care Med 1999, 25:S62.
17. Hammond GL, Smith CL, Paterson NA, et al. A role for corticosteroid binding globulin in the delivery of cortisol to activated neutrophils. J Clin Endocriniol Metab 1990, 71:34-39.
18. Beishuizen A, van Lijf JH, Lekkerkerker JF, et al. The low dose (1 microgram) ACTH stimulation test for assessment of the hypothalamic-pituitary adrenal axis. Neth J Med 2000, 56:91-99.
19. Marik PE, Zaloga GP Adrenal insufficiency during septic shock. Crit Care Med 2003, 31:141-145.
20. Annane D, Sebillle V, Charpentier C, et al. Effect of treatment with low dose hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288:862-887.
21. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective randomized double blind, single center study. Crit Care Med 1999, 27:723-732.
22. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta analysis of the literature. Crit Care Med 1995, 23:1430-1439.
23. Sharshar T, Carlier R, Blanchard A, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002, 30:497-500.
24. Krismer AC, Wenzel V, Mayr VD, et al. Arginine vasopressin during cardiopulmonary resuscitation and vasodilatory shock: current experience and future perspectives. Curr Opin Crit Care 2001, 7:157-169.
25. Linder KH, Dirks B, Strohmenger HU, et al. Randomised comparison of epinephrine and vasopressin in patients with out-hospital ventricular fibrillation. Lancet 1997, 349:535-537.
26. Stiell IG, Hebert PC, Wells GA, et al. Vasopressin versus epinephrine for inhospital cardiac arrest: a randomized controlled trial. Lancet 2001, 359:105-109.
27. Liedel JL, Meadow W, Nachman J, et al. Use of vasopressin in refractory hypotension in children with vasodilatory shock: five cases and review of the literature. Pediatr Crit Care Med 2002, 3:15-18.
28. Shibasaki T, Hotta S, Wakabayashi I Brain vasopressin is involved in the stress induced suppression of immune function in the rat. Brain Res 1998, 808:84-92.
29. Bell J, Adler MW, Greenstein JI The effect of arginine vasopressin on autologous mixed lymphocyte reactions. Int Immunopharmacol 1992, 14:93-103.
30. Chikanza IC, Petrou P, Chrousos G Perterbations of arginine vasopressin secretion during inflammatory stress, pathophysiologic implications. Ann N Y Acad Sci 2000, 917:825-834.
31. Besedovsky HO, Del Rey A Immune-neuro-endocrine Interactions: facts and hypotheses. Endocr Rev 1996, 17:64-102.
32. Yang H, Wang L, Huang CS, et al. Plasticity of GAP-43 innervation of the spleen during immune response in the mouse: evidence for axonal sprouting and redistribution of the nerve fibers. Neuroimmunomodulation 1998, 5:53-60.
33. + T and B lymphocyte function in vitro and in vivo. Pharmacol Rev 2001, 53:487-525.
34. Kohm AP, Sanders VM Norepinephrine, a messenger from the brain to the immune system. Immunol Today 2000, 21:539-542.
35. Devins SS, Miller A, Herndon BL, et al. Effects of dopamine on t-lymphocyte proliferative responses and serum prolactin concentration in critically ill patients. Crit Care Med 1992, 20:1644-1649.
36. Van den Berghe G, de Zegher F Anterior pituitary function during critical illness and dopamine treatment. Crit Care Med 1996, 24:1580-1590.
37. Freeman ME, Kanycska B, Lerany A, et al. Prolactin: structure, function and regulation of secretion. Physiol Rev 2000, 80:1523-1631.
38. Noel GL, Suh HK, Stone JG, et al. Human prolactin and growth hormone release during surgery and other conditions of stress. J Clin Endocrinol Metab 1972, 35:840-851.
39. Fletcher-Chiappini SE, Compton MM, La Voie HA, et al. Glucocorticoid-prolactin interactions in NB2 lymphoma cells: anti-proliferative versus anticytolytic effects. Proc Soc Exp Biol Med 1993, 202:345-352.
40. Velkeniers B, Dogusan Z, Naessens F, et al. Prolactin, growth hormone, and the immune system in humans. Cell Mol Life Sci 1998, 54:1102-1108.
41. Russell DH, Kibler R, Matrisian L, et al. Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine. J Immunol 1985, 134:3027-3031.
42. Jorgensen C, Sany J Prospects and advances in hormonal immunomodulatory therapy. Ballieres Best Pract Res Clin Rheumatol 1996, 10:379-392.
43. Chaudry IH, Ayala A, Ertel W, et al. Hemorrhage and resuscitation: immunological aspects. Am J Physiol 1990, 259(4 pt 2):R663-R678.
44. Kayne RD, Burrow GN Anterior pituitary function in women with postpartum hemorrhage. Yale J Biol Med 1978, 51:151-156.
45. Felmet K, Hall MA, Carcillo JA, et al: Unpublished manuscript. 2003.
46. Richards SM, Murphy WJ Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function. J Neuroimmunol 2000, 109:56-62.
47. Berczi I, Chalmers IM, Nagy E, et al. Immune effects of neuropeptides. Baillieres Best Pract Res Clin Rheumatol 1996, 10:227-259.
48. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001, 345:1359-1367.
49. Carroll P Treatment with growth Hormone and insulin-like growth factor-1 in critical illness. Best Pract Res Clin Endocrinol Metab 2001, 15:435-451.
50. Gilpin DA, Barrow RE, Rutan RL, et al. Recombinant human growth hormone accelerates wound healing in children with large cutaneous burns. Ann Surg 1994, 220:19-24.
51. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999, 341:785-792.
52. de Groof F, Joosten KF, Janssen JA, et al. Acute stress response in children with meningococcal sepsis: important differences in the growth hormone/insulin-like growth factor I axis between nonsurvivors and survivors. J Clin Endocrinol Metab 2002, 87:3118-3124.
53. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001, 86:1868-1870.
54. Holaday JW, D'Amato RJ, Ruvio BA, et al. Adrenalectomy unlocks pressor responses to naloxone in endotoxic shock: evidence for sympathomedullary involvement. Circ Shock 1983, 11:201-210.
55. Long JB, Lake CR, Reid AA, et al. Effects of naloxone and thyrotropin releasing hormone on plasma catecholamines, corticosterone, and arterial pressure in normal and endotoxemic rats. Circ Shock 1986, 18:1-10.
56. Lewis JW, Shavit Y, Terman GW, et al. Stress and morphine affect survival of rats challenged with a mammary ascites tumor (MAT13762B). Nat Immune Cell Growth Regul 1983, 3:43-50.
57. Yeager MP, Collacchiop TA Effect of morphine on growth of metastatic colon cancer in vivo. Arch Surg 1991, 126:454-456.
58. Carr DJ, France CP Immune alterations in chronic morphine treated rhesus monkeys. Adv Exp Med Biol 1993, 335:35-39.
59. Hall DM, Suo JL, Weber RJ Opioid mediated effects on the immune system: sympathetic nervous system involvement. J Neuroimmunol 1998, 83:29-35.
60. Houghtling RA, Mellon RD, Tan RJ, et al. Acute effects of morphine on blood lymphocyte proliferation and plasma IL-6 levels. Ann N Y Acad Sci 2000, 917:771-777.
61. Roy S, Loh HH Effects of opioids on the immune system. Neurochem Res 1996, 11:1375-1386.
62. Madden JJ, Whaley WL, Ketelsen D Opiate binding sites in the cellular immune system: expression and regulation. J Neuroimmunol 1998, 83:57-62.
63. Lichtenauer-Kaligis EG, van Hagen PM, Lamberts SW, et al. Somatostatin receptor subtypes in human immune cells. Eur J Endocrinol 2000, 143:S21-S25.
64. Oomen SP, Hofland LJ, van Hagen PM, et al. Somatostatin receptors in the haematopoietic system. Eur J Endocrinol 2000, 143:S9-S14.
65. Weinstock JV, Elliot D The somatostatin immunoregulatory circuit present at sites of chronic inflammation. Eur J Endocrinol 2000, 143:S15-S19.
66. Baughn JA, Bucala R Macrophage migration inhibitory factor. Crit Care Med 2002, 30:S27-S35.
67. Beishuizen A, Thijs LG, Haanen C, et al. Macrophage migration inhibitory factor and hypothalamic pituitary adrenal function during critical illness. J Clin Endocrinol Metab 2001, 107:13-20.
68. Dimri R, Sharabi Y, Shoham J Specific inhibition of glucocorticoid-induced thymocyte apoptosis by substance P. J Immunol 2000, 164:2479-2486.
69. Harrion S, Geppetti P Substance P. Int J Biochem Cell Biol 2001, 33:555-576.
70. Levite M Nerve driven immunity: the direct effects of neurotransmitters on T-cell function. Ann N Y Acad Sci 2000, 917:307-321.
71. Volk HD, Reinke P, Krausch D, et al. Monocyte deactivation rationale for a new therapeutic strategy in sepsis. Intensive Care Med Suppl 1996, 4:S474-S481.
72. Ledingham IM, Watt I Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983, 1:1270.
73. Absalom A, Pledger D, Kong A Adrenocortical function in critically ill patients 24 hours after a single dose of etomidate. Anaesthesia 1999, 54:861-867.
74. Catalano RD, Parameswaran V, Ramachandran J, et al. Mechanisms of adrenocortical depression during Escherichia coli shock. Arch Surg 1984, 119:145-150.
75. Bamberger CM, Schulte HM, Chrousos GP Molecular determinants of glucocorticoid receptor function and tissue sensitivity. Endocr Rev 1996, 17:221-244.
76. Van den Berghe G The neuroendocrine response to stress is a dynamic process. Best Pract Res Clin Endocrinol Metab 2001, 15:405-419.